Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Nov 9, 2023 (3 years ago)

neostigmine methylsulfate 5 mg/5 mL Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

neostigmine methylsulfate 5 mg/5 mL Injection, (Concentration = 1mg/mL), 5 mL fill 6 mL Syringe, Rx Only, SCA Pharma, 755 Rainbow Rd., Windsor, CT 06095, NDC 70004-0750-09, Bar Code 70004075009

Affected NDC 70004-0750-09

Compare with the code on your package — it is the most precise check available.

Drug: Neostigmine

Recalling firm
SCA Pharmaceuticals, LLC
NDC code
70004-0750-09
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0413-2024 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Neostigmine recalls

See all
Class II · Moderate risk

neostigmine 5 mg/5mL

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Terminated Sterility / contamination Central Admixture Pharmacy Services, Inc. D-0982-2023

Other recalls by SCA Pharmaceuticals, LLC

All 2023 recalls